12621, 1000 PMOriginality ReportPage 1 of 6httpsclas

1/26/21, 10:00 PMOriginality Report
Page 1 of 6https://class.waldenu.edu/webapps/mdb-sa-
BBLEARN/originalityReport/…course_id=_16782097_1&includ
eDeleted=true&print=true&download=true
%%63
SafeAssign Originality Report
NURS-6521D-5/NURS-6521N-5/NURS-6521A-5-Adv… •
SafeAssign Drafts
%%63Total ScoreTotal Score:: High risk
Dera Ogudo
Submission UUID: ee4ea50b-fd85-24bc-6924-a746b0154e78
Total Number of ReTotal Number of Re……
1
Highest MatchHighest Match
63 %
WK8Assgn_Ogudo.docx
Average MatchAverage Match
63 %
Submitted onSubmitted on
01/26/21
09:48 PM CST

Average Word CountAverage Word Count
813
Highest: WK8Assgn_Ogud…
%%63Attachment 1
Inst itut ional databaseInst itut ional database ( (77))
Student paperStudent paper Student paperStudent paper
Student paperStudent paper
Student paperStudent paper Student paperStudent paper
Top sourcesTop sources ( (33))
Excluded sourcesExcluded sources ( (00))
View Originality Report - Old Design
Word Count: 813
WK8Assgn_Ogudo.docx
22 55 44
11 66 33
77
22 Student paperStudent paper 55 Student paperStudent paper
44 Student paperStudent paper
1
3

Alzheimer’s Case Study Analysis
Dera Ogudo
Walden University
January 26, 2021
Alzheimer’s Disease Case Study It can be a daunting task for a
skilled practitioner to carry a diagnosis of Alzheimer’s disease
(AD). Diagnosis of
dementia must have at least two major cognitive functions for it
to be affected sufficiently to impede daily routines. These entail
the capacity
to reason, language skills, memory, visual protection, and
ability to solve problems. Diagnosis of dementia does not have
a definite test, thus,
there is a need for clinicians to conduct several assessments like
neurophysiological and cognitive tests in order to determine
judgment, cogni-
tion, memory, attention, vocabulary, and thinking. The case
study entails a seventy-six-year-old man who is suspected of
having Alzheimer’s
disease. The case conclusion is derived on the information that
is presented by his son and there lacked organic illness process
during inspec-
tion. His behavioral changes began 2 years ago, which
comprised of apathy, changes in his personality, which was l ater
followed by diffi-
culties when speaking and loss of memory. When conducting a
clinical interview, confabulation was also detected, self-
ascertained eu-
thymic mood and speech. The patient also showed signs of
impaired insight and judgment and also lacked impulse control.
The pa-
tient does not show signs of suicide ideation and he is

diagnosed with a condition called neurocognitive disorder that
is linked to Alzheimer’s
11
22
33 44
https://class.waldenu.edu/webapps/mdb-sa-
BBLEARN/originalityReport?attemptId=e560c6e4-8f80-47de-
ba1e-
bf571388590b&course_id=_16782097_1&download=true&inclu
deDeleted=true&print=true&force=true
Source MatchesSource Matches ( (2020))
Student paper 65%
Student paper 68%
tient does not show signs of suicide ideation and he is
diagnosed with a condition called neurocognitive disorder that
is linked to Alzheimer’s
disease. The first step or intervention that will be carried out
involves Donepezil 5mg during bedtime. Donepezil use among
individuals
with Alzheimer’s disease has been analyzed for many years.
This prescription is an inhibitor of acetycholinesterase, which
raises the levels of

acetylcholine in a human brain and while compensating the
decreased task of cholinergic neurons (Birks and Harvey, 2018).
The impact of
donepezil on Alzheimer’s patients has been analyzed through
random control tests via randomized clinical assessment tests.
The results indi-
cated that the drug is effective in 3 key areas when managing
the condition. These aspects include cognition, behavior, and
functional abil-
ity (Li et al., 2018). These three aspects were the main parts
that were greatly affected in this case and aimed at limiting his
value of life. As
the case portrays, the patient showed significant changes in his
personality which impacted on how he engaged in his daily
activities negative-
ly. The outcomes differ when a person uses donepezil because a
patient can develop complications alongside minimal clinical
advantages.
The patient made complaints such as lack of appetite and weight
loss, diarrhea, nausea, and vomiting, cases that have been
reported by
patients who have used the medication (Kumar and Sharma,
2019). The second decision comprised of cognitive behavioral
treatment; a
method that has been determined to be effective among people
who are at the early stages of the condition. There is very l ittle
or limited evi-
dence that support psychosocial interventions among
Alzheimer’s patients (Forstmeier et al., 2015). However, the
available empirical data sup-
porting this approach remains limited. Some experts support the
use of behavioral interventions claiming they are the most
suitable for indi-
viduals with neuropsychiatric symptoms. Thus, these will be
employed to help the patient improve his behavior, and

specifically focus on de-
creasing apathy and at the same time help him improve his self-
control. By improving his mood, he will be able to improve his
quality of life
and his capacity to get involved in acts that will better his
intellectual status. Lastly, the third intervention will involve
engaging members of his
family in the process because it will assist to strengthen his
behavior which is important for him. Numerous studies have
proved that most el-
derly people don’t get the kind of care they wish from members
of their families (Smith et al., 2017). This limits the capacity to
analyze how ef-
fective an intervention is, because some results may be as a
result of using the wrong type of medication. The aim is to
ensure that the patient
is fully supported by his family members in his daily activities
and interactions because it proven to impact positively on the
emotional and in-
tellectual status of a person with Alzheimer’s disease.
References
Birks, J. S., & Harvey, R. J. (2018). Donepezil for dementia due
to Alzheimer’s disease. Cochrane Database of systematic
reviews,
(6). Forstmeier, S., Maercker, A., Savaskan, E., & Roth, T.
(2015). Cognitive behavioural treatment for mild Alzheimer’s
patients and their
caregivers (CBTAC): study protocol for a randomized
controlled trial. Trials, 16(1), 526. How is Alzheimer’s Disease
Treated? (2020). NIH
Kumar, A., & Sharma, S. (2019). Donepezil. In StatPearls

[Internet]. StatPearls Publishing. Li, Q., He, S., Chen, Y., Feng,
F., Qu, W., &
Sun, H. (2018). Donepezil-based multi functional cholinesterase
inhibitors for treatment of Alzheimer’s disease. European
journal of
medicinal chemistry, 158, 463-477.
55
22
66
22
22
22 55 22
55
22
77 22 22
55 22
Smith, D., Lovell, J., Weller, C., Kennedy, B., Winbolt, M.,
Young, C., & Ibrahim, J. (2017). A systematic review of
medication non-adher-
ence in persons with dementia or cognitive impairment. PloS
one, 12(2).
22 22
1
Student paper

His behavioral changes began 2 years ago, which comprised of
apathy,
changes in his personality, which was later followed by
difficulties when
speaking and loss of memory.
Original source
His behavior changes began 2 years ago and included apathy,
personality
changes, and memory loss
2
Student paper
When conducting a clinical interview, confabulation was also
detected, self-
Student paper 63%
Student paper 71%
Student paper 67%
Student paper 68%
When conducting a clinical interview, confabulation was also

detected, self-
ascertained euthymic mood and speech.
Original source
Confabulation is also noticed during the clinical interview,
speech, and self-
reported euthymic mood
3
Student paper
The patient also showed signs of impaired insight and judgment
and also
lacked impulse control.
Original source
His judgment, insight., and impulse control are impaired
4
Student paper
The patient does not show signs of suicide ideation and he is
diagnosed with
a condition called neurocognitive disorder that is linked to
Alzheimer’s
disease.
Original source
The ideation of suicide was not reported, and the patient is
diagnosed with a
neurological disorder linked to Alzheimer's disease

5
Student paper
Donepezil use among individuals with Alzheimer’s disease has
been analyzed
for many years. This prescription is an inhibitor of
acetycholinesterase, which
raises the levels of acetylcholine in a human brain and while
compensating
the decreased task of cholinergic neurons (Birks and Harvey,
2018).
Original source
The use of donepezil among patients diagnosed with
Alzheimer's disease has
been validated for many decades This drug's mechanism of
action is based
on the fact that it is an acetylcholinesterase inhibitor, which
raises acetyl-
choline levels in the brain and regains the impaired function of
cholinergic
neurons (Birks and Harvey, 2018)
2
Student paper
The impact of donepezil on Alzheimer’s patients has been
analyzed through
random control tests via randomized clinical assessment tests.
Original source

An assessment of randomized clinical trials analyzed the impact
that
donepezil has on patients with Alzheimer’s using randomized
control trials
Student paper 87%
Student paper 63%
Student paper 76%
Student paper 100%
Student paper 100%
6
Student paper
These aspects include cognition, behavior, and functional
ability (Li et al.,
2018).
Original source
behavior, cognition, and functional ability (Li et al., 2018)
2

Student paper
As the case portrays, the patient showed significant changes in
his personali-
ty which impacted on how he engaged in his daily activities
negatively.
Original source
As indicated in the case, he had significant personality changes
that negative-
ly impacted his engagement in activities of interest
2
Student paper
The patient made complaints such as lack of appetite and weight
loss, diar-
rhea, nausea, and vomiting, cases that have been reported by
patients who
have used the medication (Kumar and Sharma, 2019).
Original source
The patient complained of side effects such as loss of weight
and appetite,
vomiting, nausea, and diarrhea, which have been reported
among patients
using this medication (Kumar and Sharma, 2019)
2
Student paper

S., & Harvey, R.
Original source
S., & Harvey, R
5
Student paper
Donepezil for dementia due to Alzheimer’s disease.
Original source
Donepezil for dementia due to Alzheimer's disease
eDeleted=true&print=true&download=tr ue
Student paper 100%
Student paper 100%
Student paper 100%
Student paper 100%
Student paper 100%
Student paper 100%

2
Student paper
Cochrane Database of systematic reviews, (6). Forstmeier, S.,
Maercker, A.,
Savaskan, E., & Roth, T.
Original source
Cochrane Database of systematic reviews, (6) Forstmeier, S.,
Maercker, A.,
Savaskan, E., & Roth, T
5
Student paper
Cognitive behavioural treatment for mild Alzheimer’s patients
and their care-
givers (CBTAC):
Original source
Cognitive behavioural treatment for mild Alzheimer’s patients
and their care-
givers (CBTAC)
2
Student paper
study protocol for a randomized controlled trial. Trials, 16(1),
526. How is
Alzheimer’s Disease Treated?

Original source
study protocol for a randomized controlled trial Trials, 16(1),
526 How is
Alzheimer’s Disease Treated
7
Student paper
Kumar, A., & Sharma, S.
Original source
Kumar, A., & Sharma, S
2
Student paper
In StatPearls [Internet].
Original source
In StatPearls [Internet]
2

Student paper 100%
Student paper 100%
Student paper 100%
Student paper
Li, Q., He, S., Chen, Y., Feng, F., Qu, W., & Sun, H.
Original source
Li, Q., He, S., Chen, Y., Feng, F., Qu, W., & Sun, H
5
Student paper
Donepezil-based multi functional cholinesterase inhibitors for
treatment of
Alzheimer’s disease.
Original source
Donepezil-based multi-functional cholinesterase inhibitors for
treatment of
Alzheimer's disease
2
Student paper
European journal of medicinal chemistry, 158, 463-477. Smith,
D., Lovell, J.,
Weller, C., Kennedy, B., Winbolt, M., Young, C., & Ibrahim, J.

Original source
European journal of medicinal chemistry, 158, 463-477 Smith,
D., Lovell, J.,
Weller, C., Kennedy, B., Winbolt, M., Young, C., & Ibrahim, J
2
Student paper
A systematic review of medication non-adherence in persons
with dementia
or cognitive impairment. PloS one, 12(2).
Original source
A systematic review of medication non-adherence in persons
with dementia
or cognitive impairment PloS one, 12(2)

12621, 1000 PMOriginality ReportPage 1 of 6httpsclas

Recommended

Recommended

More Related Content

More from CicelyBourqueju

More from CicelyBourqueju (20)

12621, 1000 PMOriginality ReportPage 1 of 6httpsclas